Gene · 5889
Papers3,668
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,041 to 1,060 of 3,668
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Patient Experience with a Gynecologic Oncology-Initiated Genetic Testing Model for Women with Tubo-Ovarian Cancer. | Curr Oncol | 2022 | 35621678 | PubTator, text mining | PubMed |
| Genomics and Immunomics in the Treatment of Urothelial Carcinoma. | Curr Oncol | 2022 | 35621673 | PubTator, text mining | PubMed |
| Understanding the Experience of Canadian Women Living with Ovarian Cancer through the Every Woman StudyTM. | Curr Oncol | 2022 | 35621661 | PubTator, text mining | PubMed |
| A human breast atlas integrating single-cell proteomics and transcriptomics. | Dev Cell | 2022 | 35617956 | PubTator, text mining | PubMed |
| Further refining 2020 ESGO/ESTRO/ESP molecular risk classes in patients with early-stage endometrial cancer: A propensity score-matched analysis. | Cancer | 2022 | 35617463 | PubTator, text mining | PubMed |
| AZD5305 More Tolerable than Earlier PARP Agents. | Cancer Discov | 2022 | 35616497 | PubTator, text mining | PubMed |
| Germline mutations in Chinese ovarian cancer with or without breast cancer. | Mol Genet Genomic Med | 2022 | 35608067 | PubTator, text mining | PubMed |
| Inherited bone marrow failure in the pediatric patient. | Blood | 2022 | 35605178 | PubTator, text mining | PubMed |
| Clinician-Reported Impact of Germline Multigene Panel Testing on Cancer Risk Management Recommendations. | JNCI Cancer Spectr | 2022 | 35603838 | PubTator, text mining | PubMed |
| Comprehensive Analysis of the Expression and Prognosis for RAD51 Family in Human Breast Cancer. | Int J Gen Med | 2022 | 35601003 | PubTator, text mining | PubMed |
| Apparent regional differences in the spectrum of BARD1 pathogenic variants in Spanish population and importance of copy number variants. | Sci Rep | 2022 | 35595798 | PubTator, text mining | PubMed |
| Distinct landscapes of deleterious variants in DNA damage repair system in ethnic human populations. | Life Sci Alliance | 2022 | 35595529 | PubTator, text mining | PubMed |
| Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer. | BMC Cancer | 2022 | 35578198 | PubTator, text mining | PubMed |
| High N-Cadherin Protein Expression in Ovarian Cancer Predicts Poor Survival and Triggers Cell Invasion. | Front Oncol | 2022 | 35574323 | PubTator, text mining | PubMed |
| Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS. | Cancer Treat Res Commun | 2022 | 35567913 | PubTator, text mining | PubMed |
| Resistance to DNA repair inhibitors in cancer. | Mol Oncol | 2022 | 35567571 | PubTator, text mining | PubMed |
| The Genetic and Molecular Analyses of RAD51C and RAD51D Identifies Rare Variants Implicated in Hereditary Ovarian Cancer from a Genetically Unique Population. | Cancers (Basel) | 2022 | 35565380 | PubTator, text mining | PubMed |
| Cullin 3 Exon 9 Deletion in Familial Hyperkalemic Hypertension Impairs Cullin3-Ring-E3 Ligase (CRL3) Dynamic Regulation and Cycling. | Int J Mol Sci | 2022 | 35563538 | PubTator, text mining | PubMed |
| MicroRNA-449a Inhibits Triple Negative Breast Cancer by Disturbing DNA Repair and Chromatid Separation. | Int J Mol Sci | 2022 | 35563522 | PubTator, text mining | PubMed |
| Beyond BRCA: The Emerging Significance of DNA Damage Response and Personalized Treatment in Pancreatic and Prostate Cancer Patients. | Int J Mol Sci | 2022 | 35563100 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5889/papers?page=53